Journal article
Lytic reactivation of EBV by HIV proteins and antiretroviral therapy with the heightened expression of MEF-2 oncogenes implicated in AIDS-related cancer
The microbe, v 12, 100789
Sep 2026
Featured in Collection : Drexel's Newest Publications
Abstract
Despite effective antiretroviral therapy (ART), people living with HIV (PLWH) remain at a higher risk of developing AIDS-related cancers. The factors attributed to this increased risk are multifactorial, including long-term ART use, prolonged exposure to soluble HIV proteins, and drugs of abuse. Epstein-Barr virus (EBV) is a common driver of many malignancies, such as Burkitt’s lymphoma and Hodgkin’s lymphoma. While ART effectively suppresses HIV replication, it is not curative and prolonged use imposes health risks, including an accelerated course of cancers. Herein, we investigated the effects of various factors that can impact EBV latency in PLWH in cooperation with cellular oncoproteins. EBV negative and positive lymphoblastoid cell lines were stimulated with Biktarvy (a combination of Tenofovir, Emtricitabine, and Bictegravir), recombinant HIV proteins Nef and Rev, and/or drugs of abuse, including cocaine, METH, and morphine. We observed that simulation with Nef, Rev, or ART promoted the expression of EBV genes linked to lytic reactivation, such as BZLF1 and BMRF, as well as myocyte enhancer factor (MEF)-2 family oncogenes. MEF-2 observations were confirmed at the protein level and EBV gene changes were validated in samples from people with HIV/EBV. Enhancement of EBV lytic gene expression was confirmed by the DNA level changes and by assessing the protein products of BZLF1 and BMRF1. Drugs of abuse alone did not show any significant effects; however, METH combined with ART modestly promoted viral gene expression and suppressed anti-inflammatory cytokine production in a NF-KB dependent manner, a key signaling pathway for EBV reactivation. Indeed, NF-kB inhibition reversed the impact of HIV proteins and ART on EBV latent B cells. These findings establish a link between oncogenesis and persistent HIV and prolonged use of ART, highlighting the potential oncogenic risks for these HIV-associated factors.
Metrics
1 Record Views
Details
- Title
- Lytic reactivation of EBV by HIV proteins and antiretroviral therapy with the heightened expression of MEF-2 oncogenes implicated in AIDS-related cancer
- Creators
- Alesha Philip - Drexel UniversityThomas A. Premeaux - Cornell CollegeAdhikarimayum Lakhikumar Sharma - Thomas Jefferson UniversityCabirou Mounchili Shintouo - Drexel UniversityAykan Karabudak - Doylestown HospitalLiudi Tang - Baruch S. Blumberg InstituteSalwa Ahmed - Drexel UniversityAlekhya Rani Chunduri - Drexel UniversitySai Chaitanya R. Gaekwar - Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USAElias Haddad - Drexel UniversityRyan Hoffmann - Drexel UniversityMudit Tyagi - Thomas Jefferson UniversityPooja Jain (Corresponding Author) - Drexel University
- Publication Details
- The microbe, v 12, 100789
- Publisher
- Elsevier
- Number of pages
- 13
- Grant note
- InterConsortium (Drexel/Jefferson) Pilot Funding through the NCI: R61/R33 DA058397, R01DA041746, 1R21MH126998-01A National Institute on Drug Abuse (NIDA) of the National Institutes Health: R61/R33 DA058397 Thomas Jefferson University: 108-18007-908107
These studies are directly supported by a InterConsortium (Drexel/Jefferson) Pilot Funding through the NCI-accredited Sydney Kimmel Comprehensive Cancer Center to PJ & MT. PJ was also supported by National Institute on Drug Abuse (NIDA) of the National Institutes Health under Award Number R61/R33 DA058397 while MT was supported by R01DA041746, 1R21MH126998-01A, and Thomas Jefferson University internal grant #108-18007-908107.
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology; Neurobiology and Anatomy; Infectious Diseases (and HIV Medicine)
- Web of Science ID
- WOS:001866566100001
- Other Identifier
- 991022205557004721